Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCL
Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).
Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).
Patients who are refractory to chemotherapy now have CAR T-cell therapy as an option, according to Karmali. The SCHOLAR-1 study investigated the outcomes of patients with refractory DLBCL, which showed a median overall survival of 6 months. The addition of CAR T-cell therapy has benefitted this patient population, says Karmali.
